Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flanvotumab
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Flanvotumab (IMC-20D7S) is a recombinant human IgG1 monoclonal antibody that targets tyrosinase-related protein 1 (TYRP1, also known as gp75), a transmembrane glycoprotein specifically expressed in melanocytes and melanoma cells. By binding to TYRP1 on the surface of melanoma cells, flanvotumab induces immune-mediated antitumor effects primarily through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These mechanisms recruit natural killer cells and other immune effectors to destroy TYRP1-positive tumor cells. Flanvotumab was developed by ImClone Systems and Eli Lilly for the treatment of advanced melanoma. In phase I clinical trials, it demonstrated a favorable safety profile with evidence of antitumor activity in patients with relapsed or refractory melanoma[2][4][5][8].
- Other names
- Gp75 monoclonal antibody (melanoma)Gp75 mAb (melanoma)GP75/TRP1 mAbs (melanoma)
02
Targets
TYRP1 (Tyrosinase-related protein 1)
Beyond the preview
Go deeper on flanvotumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flanvotumab.